Date: 9/10/2023	
Your Name:_Naofumi Hara	
Manuscript Title:_ CDK4/6 signaling attenu	uates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lu	ung cancer_
Manuscript number (if known):	·
· · · · ·	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	-	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Doumont or honorovia for	None	
Э	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		· · ·
9	Participation on a Data	None	
9	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
	1		

NH declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date:_9/10/2023
Your Name: Eiki Ichihara
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time former Cinese the initial alor	
		Time frame: Since the initial plan	nning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past 36 n	nonths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Takeda Pharmaceutical	Research funding
		Company Limited	
		Pfizer Japan Inc.	Research funding
		AstraZeneca K.K.	Research funding
		MSD	Research funding
		Janssen Pharmaceutical	Research funding
		К.К.	
		Nippon Kayaku Co.,Ltd.	Research funding

3	Royalties or licenses	None	· · · · · · · · · · · · · · · · · · ·
4	Consulting fees	None	
-			
5	Payment or honoraria for	AstraZeneca K.K.	honoraria
	lectures, presentations, speakers bureaus,	Takeda Pharmaceutical	honoraria
	manuscript writing or	Company Limited	
	educational events	Janssen Pharmaceutical	honoraria
		K.K.	
		Chugai Pharmaceutical	honoraria
		Co.,Ltd.	
		Pfizer Japan Inc.	honoraria
		Novartis Pharma K.K.	honoraria
		ONO PHARMACEUTICAL	honoraria
		CO., LTD.	-
		Merck & Co., Inc.	honoraria
		Bristol-Myers Squibb	honoraria
		Company	
		Eli Lilly Japan K.K.	honoraria
		Nippon Boehringer	honoraria
		Ingelheim Co., Ltd.	1
6	Payment for expert	Nippon Kayaku Co.,Ltd. None	honoraria
0	testimony	None	
7	Support for attending	None	
	meetings and/or travel		
	Determine a lange of the second second		
8	Patents planned, issued or pending	None	
	penang		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	L
	materials, drugs, medical	1	

	writing, gifts or other services		
13	Other financial or non- financial interests	None	
_			

El received honoraria from AstraZeneca K.K., Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co.,Ltd., Pfizer Japan Inc., Novartis Pharma K.K., ONO PHARMACEUTICAL CO., LTD., Merck & Co., Inc., Bristol-Myers Squibb Company, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., and Nippon Kayaku Co.,Ltd. El received additional research funding from Takeda Pharmaceutical Company Limited, Pfizer Japan Inc., AstraZeneca K.K., MSD, Janssen Pharmaceutical K.K., and Nippon Kayaku Co.,Ltd.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_9/10/2023
Your Name:_Hirohisa Kano
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this	Specifications/Comments
		relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of the w	· · ·
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	
5		Bristol-Myers Squibb K.K.	Honoraria

	Payment or honoraria for	AstraZeneca K.K.	Honoraria
	lectures, presentations,	Chugai Pharmaceutical Co., Ltd.	Honoraria
	speakers bureaus,	Ono Pharmaceutical Co., Ltd.	Honoraria
	manuscript writing or	MSD K.K.	Honoraria
	educational events		
		1	
6	Payment for expert	None	
-	testimony		
		· · · ·	
7	Support for attending	None	
	meetings and/or travel		
		· .	
8	Detents play and investor	Mana	
ð	Patents planned, issued or pending	None	
	pending		· · · · · · · · · · · · · · · · · · ·
9	Participation on a Data	None	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
14	materials, drugs, medical		
	writing, gifts or other	· · · · · · · · · · · · · · · · · · ·	
	services		
13	Other financial or non-	None	
	financial interests		
			· · · · · · · · · · · · · · · · · · ·

HK received honoraria from AstraZeneca, Chugai Pharmaceutical, Ono Pharmaceutical, MSD, and Bristol-Myers Squibb.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

.

Date:_9/10/2023
Your Name:_Chihiro Ando
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	· · · ·		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

	Y#1		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
-	financial interests		
		· · · · · · · · · · · · · · · · · · ·	

CA declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date:_9/10/2023
Your Name:_Ayako Morita
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer _
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

	T	1	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	None	
7	Support for attending	None	
	meetings and/or travel		
-			
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	-		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
	<u>u=u</u> :		

AM declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

_X I certify that I have answered every question and have not altered the wording of any of the questions on this

orm.

.

.

Date:_9/10/2023
Your Name:_Tatsuya Nishi
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
m	Royalties or licenses	None	
4	Consulting fees	None	

	1		·····
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
•	meetings and/or travel		
	incerings and/or daver	ann	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	, market
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy	u u	
	group, paid or unpaid		
11	Stock or stock options	None	
**		NOILE	
10		••	
12	Receipt of equipment,	None	/ 1/37 1/10
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

TN declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

___X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date:_9/10/2023
Your Name:_Sachi Okawa
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,	The demonstration of the second	
	medical writing, article		<u> </u>
	processing charges, etc.)		
	No time limit for this item.		
			- 1 9. 14
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated	······································	
	in item #1 above).		
3	Royalties or licenses	None	
i	· · · · · · · · · · · · · · · · · · ·		
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	· · · · · · · · · · · · · · · · · · ·
	financial interests	· · · · · · · · · · · · · · · · · · ·	

SO declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: <u>9/10/2023</u>			
'our Name:_Takamasa Nakasuka			
Nanuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>			
inhibitors in EGFR mutant non-small cell lung cancer			
/anuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.	*	
		· · · · · · · · · · · · · · · · · · ·	
_		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	·····
4	Consulting fees	None	

<u> </u>			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	· · · · · · · · · · · · · · · · · · ·	
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		· · · · · · · · · · · · · · · · · · ·
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical	None	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
		1	

NT declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

__X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 9/10/2023
Your Name:_Atsuko Hirabae
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

		1	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

AH declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

_X_I certify that I have answered every question and have not altered the wording of any of the questions on this

.

Date: 9/10/2023
Your Name:_Masaya Abe
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		······································
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
-		· · · · · · · · · · · · · · · · · · ·	

MA declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

•

Date:_9/10/2023
Your Name:_Noboru Asada
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plann	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 mo	onths
2	Grants or contracts from any entity (if not indicated in item #1 above).	Novartis Pharma K.K.	Research grant to me
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	Novartis Pharma K.K.	Honoraria for lectures/presentation
	lectures, presentations,	Kyowa Kirin Co., Ltd.	Honoraria for lectures/presentation
	speakers bureaus,	AbbVie GK	Honoraria for lectures/presentation
	manuscript writing or	Chugai Pharmaceutical Co.,Ltd.	Honoraria for lectures/presentation
	educational events	Meiji Seika Pharma Co., Ltd.	Honoraria for lectures/presentation
		Otsuka Pharmaceutical Co., Ltd.	Honoraria for lectures/presentation
		Asahi Kasei Pharma Corporation	Honoraria for lectures/presentation
		Nippon Shinyaku Co., Ltd.	Honoraria for lectures/presentation
		Astellas Pharma Inc.	Honoraria for lectures/presentation
		Sanofi K.K.	Honoraria for lectures/presentation
6	Payment for expert	None	
	testimony		
-			
7	Support for attending	None	
[meetings and/or travel		
1			
8	Patents planned, issued or	None	
°	pending		-
	pending		
9	Participation on a Data	Nana	
9	Safety Monitoring Board or	None	
	Advisory Board		
	-	NI	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	News	
11	Stock or stock options	None	
12	Dessist of equipment	Nege	
12	Receipt of equipment,	None	· · · · · · · · · · · · · · · · · · ·
	materials, drugs, medical	<u> </u>	
	writing, gifts or other services		
12	services Other financial or non-	News	
13		None	
	financial interests		
	l		

NA received honoraria from Novartis Pharma, Kyowa Kirin, AbbVie, Chugai Pharmaceutical, Meiji Seika Pharma, Otsuka Pharmaceutical, Asahi Kasei Pharma, Nippon Shinyaku, Astellas Pharma, Sanofi. NA received additional research funding from Novartis Pharma.

.

Please place an "X" next to the following statement to indicate your agreement:

.

.

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

· --

Date: <u>9/10/2023</u>
Your Name: <u>_Kiichiro Ninomiya</u>
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this	Specifications/Comments
		relationship or indicate none (add rows as	(e.g., if payments were made to you or
~		needed)	to your institution)
		Time frame: Since the initial planning of the	work
1	All support for the present	None	
	manuscript (e.g., funding,	· · · · · · · · · · · · · · · · · · ·	
	provision of study materials,		
	medical writing, article		· · · · · · · · · · · · · · · · · · ·
	processing charges, etc.)		
	No time limit for this item.	**	
		Time frame: past 36 months	
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
_			
4	Consulting fees	None	
5		AstraZeneca K.K.	Honoraria, made to me

		Deskuta ser ta sella sin. O ta ta t	····
	Payment or honoraria for	Boehringer Ingelheim Co., Ltd.	Honoraria, made to me
	lectures, presentations,	Kyowa Kirin Co., Ltd.	Honoraria, made to me
	speakers bureaus,	Eli Lilly Japan K.K.	Honoraria, made to me
	manuscript writing or	Chugai Pharmaceutical Co., Ltd.	Honoraria, made to me
	educational events	Nippon Kayaku Co., Ltd.	Honoraria, made to me
		TAIHO Pharmaceutical Co., Ltd.	Honoraria, made to me
		MSD K.K.	Honoraria, made to me
		Ono Pharmaceutical Co., Ltd.	Honoraria, made to me
		Takeda Pharmaceutical Company Limited	Honoraria, made to me
		Pfizer Japan Inc.	Honoraria, made to me
		Bristol-Myers Squibb K.K.	Honoraria, made to me
		Pfizer Inc.	Honoraria, made to me
		Elekta K.K.	Honoraria, made to me
		Janssen Pharmaceutical K.K.	Honoraria, made to me
		Dalichi Sankyo	Honoraria, made to me
6	Payment for expert	None	
	testimony		
	,		
7	Support for attending	None	
	meetings and/or travel		
	meetings and/or duver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	+
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
		· · · · · · · · · · · · · · · · · · ·	
	I	1	

KN received honoraria from AstraZeneca, Boehringer Ingelheim, Kyowa Kirin, Eli Lilly Japan, Chugai Pharmaceutical, Nippon Kayaku, TAIHO Pharmaceutical, MSD, Ono Pharmaceutical, Takeda Pharmaceutical, Pfizer Japan, Bristol-Myers Squibb, Pfizer, Elekta, Janssen Pharmaceutical, and Daiichi Sankyo.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: <u>9/10/2023</u>
Your Name: Go MAKIMOTO
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to your
		none (add rows as needed)	institution)
		Time frame: Since the initial plannin	g of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 mon	ths
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	

[Church Dhamman and the LOG - 14-1	
	lectures, presentations,	Chugai Pharmaceutical Co., Ltd.	Honoraria
	speakers bureaus,	Novartis International AG	Honoraria
	manuscript writing or	Kyowa Kirin Co., Ltd.	Honoraria
	educational events	Merck & Co., Inc.	Honoraria
i		ONO PHARMACEUTICAL CO., LTD.	Honoraria
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
<u> </u>	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
-	services		
13	Other financial or non-	None	
	financial interests		

Go Makimoto received honoraria from Chugai Pharmaceutical Co., Ltd., Norartis International AG, Kyowa Kirin Co., Ltd., Merck & Co., Inc., and ONO PHARMACEUTIAL CO., LTD..

Please place an "X" next to the following statement to indicate your agreement:

<u>X</u> I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: 9/10/2023
Your Name:_Masanori Fujii
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

	·····		
5	Payment or honoraria for	None	
	lectures, presentations,		· · · · · · · · · · · · · · · · · · ·
	speakers bureaus,		
	manuscript writing or		
	educational events	,	
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
	meetings and/or traver		
8	Patents planned, issued or	None	
0	pending		
	i penuing		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		· · · · · · · · · · · · · · · · · · ·
	writing, gifts or other		
	services		
13	Other financial or non-	None	
тЭ	financial interests	None	
		L	.

MF declare no conflicts of interest regarding this study.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

form.

Date:_9/10/2023
Your Name:_Toshio Kubo
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have	Specifications/Comments
		this relationship or indicate none (add	(e.g., if payments were made to you or
		rows as needed)	to your institution)
		Time frame: Since the initial planning of th	e work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 months	
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5		Bristol-Myers Squibb K.K.	me

			10 0/04 (817) 000 0
	Payment or honoraria for	Taiho Pharmaceutical Co., Ltd.	me
	lectures, presentations,	Kyowa Hakko Kirin Co., Ltd.	me
	speakers bureaus,	AstraZeneca K.K.	me
	manuscript writing or	Ono Pharmaceutical Co., Ltd.	me
	educational events	Nippon Kayaku Co., Ltd.	me
		Chugai Pharmaceutical Co., Ltd.	me
		MSD K.K.	me
		Pfizer Japan Inc.	me
		Eli Lilly Japan K.K.	me
		Novartis International AG	me
		Boehringer Ingelheim Co., Ltd.	me
		Towa Pharmaceutical Co., Ltd.	me
6	Payment for expert	None	
Ŭ	testimony		
	cestimony		
7	Support for attending	None	
1	meetings and/or travel		
	meetings and/or traver		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		*******
12	Receipt of equipment,	Nono	
12		None	
	materials, drugs, medical		
	writing, gifts or other		
10	services		
13	Other financial or non-	None	
	financial interests		

٢

TK received honoraria from Bristol-Myers Squibb, Taiho Pharmaceutical, Kyowa Hakko Kirin, AstraZeneca, Ono Pharmaceutical, Nippon Kayaku, Chugai Pharmaceutical, MSD, Pfizer Japan, Eli Lilly Japan, Novartis International, Boehringer Ingelheim, and Towa Pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_9/10/2023
Your Name:_Kadoaki Ohashi
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you	Specifications/Comments
		have this relationship or indicate	(e.g., if payments were made to you or to
		none (add rows as needed)	your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)	New New York VIII To Ale	
	No time limit for this item.		
		Time frame: past 36 month	IS
2	Grants or contracts from	Boehringer Ingelheim Co., Ltd.	Research funding
	any entity (if not indicated	Chugai Pharmaceutical Co., Ltd.	Research funding
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	KO received honoraria from Lilly, Nihon kayaku, Kyowa-Kirin, Boehringer Ingelheim, Novartis, and Chugai pharmaceutical; research funding from Boehringer Ingelheim, Novartis, AstraZeneca, Eli Lilly, MSD, and Daiichi-Sankyo outside the submitted work.	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	· · · · · · · · · · · · · · · · · · ·
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Research drugs from Ono pharma, or, Novartis, Genentech under MTA outside the submitted work.	
13	Other financial or non- financial interests	None	

KO received honoraria from Lilly, Nihon kayaku, Kyowa-Kirin, Boehringer Ingelheim, Novartis, and Chugai pharmaceutical; research funding from Boehringer Ingelheim, Novartis, AstraZeneca, Eli Lilly, MSD, Chugai pharmaceutical ,and Daiichi-Sankyo outside the submitted work. KO received research drugs from Ono pharma, or, Novartis, Genentech under MTA outside the submitted work.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

.

Date:_9/10/2023
Your Name: <u>Katsuyuki Hotta</u>
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial plar	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	None	
	manuscript (e.g., funding,		1923
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		Tet.
	No time militior tins item.		
	Time frame: past 36 months		
2	Grants or contracts from	MSD K.K.	Made to me
	any entity (if not indicated in item #1 above).	AstraZeneca K.K.	Made to me
		Chugai Pharmaceutical Co., Ltd.	Made to me
		Eli Lilly Japan K.K.	Made to me
		Bristol-Myers Squibb K.K.	Made to me
		AbbVie GK	Made to me
3	Royalties or licenses	None	

	·····		• • • • • •
4	Consulting fees	None	·
	Payment or honoraria for	Dfiner lanen ine	Mada ta wa
5	lectures, presentations,	Pfizer Japan Inc. AstraZeneca K.K.	Made to me
	speakers bureaus,		Made to me
	manuscript writing or	Chugai Pharmaceutical Co., Ltd. Eli Lilly Japan K.K.	Made to me Made to me
	educational events	Takeda Pharmaceutical Co.,	Made to me
		Ltd.	
		MSD K.K.	Made to me
		Bristol-Myers Squibb K.K.	Made to me
i		Ono Pharmaceutical Co., Ltd.	Made to me
		Nippon Kayaku Co., Ltd.	Made to me
		Boehringer-Ingelheim Co., Ltd	Made to me
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	7684.0
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
			······································
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

KH received honoraria from Pfizer Japan, AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, MSD, Bristol-Myers Squibb, Ono Pharmaceutical, Nippon Kayaku, and Boehringer-Ingelheim. KH received additional research funding from MSD, AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and AbbVie. Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ς.

Date:_9/10/2023
Your Name:_Masahiro Tabata
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	None	
–	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past 36 months	
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
	· · · · · · · · · · · · · · · · · · ·		
4	Consulting fees	None	
L		<u> </u>	

5	Doursent or honoraris for		h
Э	Payment or honoraria for	ONO PHARMACEUTICAL CO., LTD.	honoraria
	lectures, presentations, speakers bureaus,	Chugai Pharmaceutical Co., Ltd.	honoraria
		AstraZeneca K.K.	honoraria
	manuscript writing or educational events	Pfizer Japan Inc.	honoraria
	educational events	Novartis Pharma K.K.	honoraria
		TAIHO Pharmaceutical Co., Ltd.	honoraria
		Bristol-Myers Squibb K.K.	honoraria
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	· · · · · · · · · · · · · · · · · · ·
8	Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	None	
	services		
13	Other financial or non- financial interests	None	

.

MT received honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, AstraZeneca, Pfizer Japan, Novartis Pharma, TAIHO Pharmaceutical, and Bristol-Myers Squibb.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

.

Date:_9/10/2023
Your Name: Yoshinobu Maeda
Manuscript Title: <u>CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase</u>
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have	Specifications/Comments
		this relationship or indicate none (add	(e.g., if payments were made to you or
		rows as needed)	to your institution)
		Time frame: Since the initial planning of the	e work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
			7. 16. A.L.
			······································
		Time frame: past 36 months	
B2	Grants or contracts from	Astellas Pharma Inc.	Research funding and Scholarship donation
	any entity (if not indicated	Asahi Kasei Pharma Corporation	Scholarship donation
	in item #1 above).	Eisai Co., Ltd.	Scholarship donation
		Otsuka Pharmaceutical Co., Ltd.	Scholarship donation
		Kyowa Kirin Co., Ltd.	Scholarship donation
		TAIHO Pharmaceutical Co., Ltd.	Scholarship donation
		Takeda Pharmaceutical Company Limited	Scholarship donation
		Chugai Pharmaceutical Co., Ltd.	Research funding and Scholarship donation
		Japan Blood Products Organization	Scholarship donation
		Nippon Shinyaku Co., Ltd.	Research funding and Scholarship donation

	Mallinckrodt Pharma K.K.	Scholarship donation
	REGIMMUNE Co, Ltd.	Scholarship donation
	AstraZeneca K.K.	Research funding and Scholarship donation
	Novartis Pharma K.K.	Research funding
	Janssen Pharmaceutical K.K.	Research funding
	Mundipharma K.K.	Research funding
		Kesearch funding
Royalties or licenses	None	
Consulting fees	None	
Payment or honoraria for	AstraZeneca K.K.	Honoraria
lectures, presentations,	Astellas Pharma Inc.	Honoraria
speakers bureaus,	Amgen K.K.	Honoraria
manuscript writing or	AbbVie GK	Honoraria
educational events	Eisai Co., Ltd	Honoraria
	Otsuka Pharmaceutical Co., Ltd.	Honoraria
	ONO PHARMACEUTICAL CO., LTD.	Honoraria
	KYORIN Pharmaceutical Co., Ltd.	Honoraria
	Kyowa Kirin Co., Ltd.	Honoraria
	Sanofi K.K.	Honoraria
	Celgene Corporation	Honoraria
	Bristol-Myers Squibb K.K.	Honoraria
	CSL Behring K.K.	Honoraria
	DAIICHI SANKYO COMPANY, LIMITED	Honoraria
	Sumitomo Dainippon Pharma Co., Ltd.	
		Honoraria
	Takeda Pharmaceutical Company Limited TERUMO CORPORATION	Honoraria
		Honoraria
	Chugai Pharmaceutical Co.,Ltd.	Honoraria
	Nippon Shinyaku Co., Ltd.	Honoraria
	Novartis Pharma K.K.	Honoraria
	Pfizer Japan Inc.	Honoraria
	Mundipharma K.K.	Honoraria
	Human Life CORD Japan Inc.	Honoraria
	Meiji Seika Pharma Co., Ltd.	Honoraria
	Janssen Pharmaceutical K.K.	Honoraria
	Yakult Honsha Co.,Ltd.	Honoraria
	Asahi Kasei Pharma Corporation.	Honoraria
	Viatris Inc.	Honoraria
	KISSEI PHARMACEUTICAL CO., LTD.	Honoraria
	KONICA MINOLTA, INC.	Honoraria
Payment for expert	None	
testimony		
Support for attending meetings and/or travel	None	

8	8 Patents planned, issued or pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

YM received honoraria form AstraZeneca, Astellas Pharma, Amgen, AbbVie, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, KYORIN Pharmaceutical, Kyowa Kirin, Sanofi, Celgene, Bristol-Myers Squibb, CSL Behring, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, TERUMO, Chugai Pharmaceutical, Nippon Shinyaku, Novartis Pharma, Pfizer Japan, Mundipharma, Human Life CORD Japan, Meiji Seika Pharma, Janssen Pharmaceutical, Yakult Honsha, Asahi Kasei Pharma, Viatris, KISSEI PHARMACEUTICAL, and KONICA MINOLTA. YM received additional research funding from Astellas Pharma, Chugai Pharmaceutical, Nippon Shinyaku, AstraZeneca, Novartis Pharma, Janssen Pharmaceutical, and Mundipharma. YM received scholarship donation from Astellas Pharma, Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical, Kyowa Kirin, TAIHO Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Japan Blood Products Organization, Nippon Shinyaku, Mallinckrodt Pharma, REGiMMUNE, and AstraZeneca.

Please place an "X" next to the following statement to indicate your agreement:

_X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:_9/10/2023
Your Name: <u>Katsuyuki Kiura</u>
Manuscript Title:_ CDK4/6 signaling attenuates the effect of epidermal growth factor receptor tyrosine kinase
inhibitors in EGFR mutant non-small cell lung cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past 36 month	15
2	Grants or contracts from any entity (if not indicated in item #1 above).	Ono Pharmaceutical Co., Ltd. Boehringer Ingelheim Co., Ltd. Novartis International AG Takeda Pharmaceutical Co., Ltd. KYORIN Pharmaceutical Co., Ltd. SHIONOGI & Co., Ltd. Nippon Kayaku Co., Ltd. Taiho Pharmaceutical Co., Ltd. Chugai Pharmaceutical Co., Ltd.	Research fundingResearch fundingResearch fundingResearch fundingScholarship donationScholarship donationScholarship donationScholarship donationScholarship donationScholarship donationScholarship donationScholarship donation

3	Royalties or licenses	None	
4	Consulting fees	Nippon Kayaku Co.,Ltd.	
		NIPRO CORPORATION	
			and the second
5	Payment or honoraria for	AstraZeneca K.K.	Honoraria for lecture
	lectures, presentations, speakers bureaus, manuscript writing or educational events	Eli Lilly Japan K.K.	Honoraria for lecture
		Taiho Pharmaceutical Co., Ltd.	Honoraria for lecture
		Chugai Pharmaceutical Co., Ltd.	Honoraria for lecture
		Pfizer Japan Inc.	Honoraria for lecture
		Ono Pharmaceutical Co., Ltd.	Honoraria for lecture
		Bristol-Myers Squibb K.K.	Honoraria for lecture
		MSD K.K.	Honoraria for lecture
		Boehringer Ingelheim Co., Ltd.	Honoraria for lecture
		Merck Biopharma Co., Ltd	Honoraria for lecture
		Nippon Kayaku Co., Ltd.	Honoraria for lecture
		Takeda Pharmaceutical Co., Ltd.	Honoraria for lecture
6	Payment for expert testimony	None	
	-		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or pending	None	
		None	
9	Participation on a Data	Nene	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10		N	
10	Leadership or fiduciary role	None	+ + + + + +
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nana	
11	Stock or stock options	None	
12	Receipt of equipment,	Nene	
		None	
	materials, drugs, medical	· · · · · · · · · · · · · · · · · · ·	
	writing, gifts or other		
12	services Other financial or non	Ness	
13	Other financial or non- financial interests	None	
		····· ································	
_	<u> </u>		

KK received honoraria from AstraZeneca, Eli Lilly Japan, TAIHO Pharmaceutical, Chugai Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Boehringer Ingelheim, Merck Biopharma, Nippon Kayaku, and Takeda Pharmaceutical. KK received consulting fee from Nippon Kayaku and NIPRO. KK received additional research funding from Boehringer Ingelheim, Ono Pharmaceutical, Novartis International, and Takeda Pharmaceutical. KK received scholarship donation from KYORIN Pharmaceutical, SHIONOGI, Nippon Kayaku, Taiho Pharmaceutical, and Chugai Pharmaceutical.

Please place an "X" next to the following statement to indicate your agreement:

__X I certify that I have answered every question and have not altered the wording of any of the questions on this form.